Revenio Group Oyj

Business and Financial Review • Dec 17, 2020

Revenio Group Corporation: Revenio updates its financial guidance for 2020

Revenio Group Corporation, Stock Exchange Release, December 17, 2020 at 17.30

Revenio updates its financial guidance for 2020

Revenio Group Corporation ("Revenio", "Company") refines its earnings guidance in terms of revenue mainly due to better-than-expected sales growth in the United States and estimates that the Company's net sales for July-December 2020 will be EUR 33.5–35.5 million and the growth to be very strong. Profitability excluding non-recurring costs is estimated to be at a strong level in accordance with the earnings guidance published on October 12, 2020.

Previous earnings guidance published on October 12, 2020:

The Covid-19 pandemic continues to cause general uncertainty on the market and weakens visibility for the remainder of the year 2020. Under these circumstances Revenio Group Corporation estimates that the company's currency-adjusted net sales for July-December of the present year will grow strongly from the previous year and the profitability excluding nonrecurring costs will be on a strong level.

Revenio Group Corporation Board of Directors

For further information, please contact:

Jouni Toijala, CEO, tel. +358 50 484 0085 jouni.toijala@revenio.fi www.revenio.fi

The Revenio Group in brief

Revenio is a health tech group operating on the international market and a global leader in ophthalmological devices. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure measurement devices under the iCare brand, retinal imaging devices and perimeters. The main tools for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).

The Revenio Group comprises Revenio Group Oyj, Icare Finland Oy, Icare USA Inc., Revenio Italy S. R. L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.

In 2019, the Group's net sales totaled EUR 49.5 million, with its operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

Revenio Group Corporation: Revenio updates its financial guidance for 2020